Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
6.79
+0.68 (11.13%)
At close: Dec 5, 2025, 4:00 PM EST
6.81
+0.02 (0.29%)
After-hours: Dec 5, 2025, 7:44 PM EST
Company Description
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders.
The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.
The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.
Enveric Biosciences, Inc.
| Country | United States |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Joseph Tucker |
Contact Details
Address: 245 First Street, Riverview II Cambridge, Massachusetts 02142 United States | |
| Website | enveric.com |
Stock Details
| Ticker Symbol | ENVB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000890821 |
| CUSIP Number | 29405E406 |
| ISIN Number | US29405E5050 |
| Employer ID | 95-4484725 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Edward Tucker Ph.D. | Chief Executive Officer and Director |
| Kevin M. Coveney CPA | Chief Financial Officer |
| Dr. Peter J. Facchini Ph.D. | Chief Innovation Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2025 | SCHEDULE 13G | Filing |
| Dec 5, 2025 | SCHEDULE 13G | Filing |
| Dec 5, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Nov 14, 2025 | 10-Q | Quarterly Report |
| Nov 14, 2025 | 8-K | Current Report |
| Nov 14, 2025 | 8-K | Current Report |
| Nov 13, 2025 | SCHEDULE 13G | Filing |
| Oct 27, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 23, 2025 | 8-K | Current Report |
| Oct 10, 2025 | PRE 14A | Other preliminary proxy statements |